Seattle biotech firm Kineta raises $1.6 million to boost its battle against disease

Kineta, a Seattle-based biotech startup, has raised an investment round worth almost $1.6 million from existing investors in the company. The investment will be used to fund continued development of the drugs that the company is working on. “This new raise comes from existing investors and shows confidence in what the Kineta team is doing and… Read More


Kineta, UW receive biodefense grant to study ways to wipe out deadly viruses like Ebola

The University of Washington, University of Texas Medical Branch and Kineta — a Seattle biotechnology upstart — have received an $8.1 million grant from the National Institute of Allergy and Infectious Diseases to develop drugs to combat Ebola, Marburg, Japanese encephalitis and other deadly diseases. “This award enables us to push further and work with more high… Read More